

REMARKS

Claims 1, 3, 6, 8-11, 17, 50, and 52-66 were pending and under consideration. In the present paper, claims 1, 50, 52, and 53 are amended and new claim 67 is presented for consideration. Thus, following entry of the present amendment, claims 1, 3, 6, 8-11, 17, 50, and 52-67 will be pending and under consideration.

Applicants acknowledge the PTO's indication of allowable subject matter in claims 52 and 53 and kindly thank the PTO for the same.

In addition, Applicants kindly thank the Examiner for the courtesy extended in an interview August 2, 2007, with Applicants' representatives Frances Putkey, Nikolaos C. George, and David C. Pauling. In the interview, each of the outstanding objections and rejections was discussed and Applicants' arguments as discussed below were presented to the Examiner. No agreement was reached regarding the patentability of the claims.

I. The Amendments to the Claims

The present paper presents an amendment to claims 1, 50, 52, and 53. The amendments to the claims are fully supported by the application as filed and therefore present no new matter. In particular, the amendment to claim 1 is supported throughout the application as filed and specifically, for example, by the specification at page 11, lines 9-15, at page p, line 6 to page 10, line 17, at page 16, line 19 to page 17, line 10, and at pages 121-122, Table 4. The amendments to claims 50, 52, and 53 merely cancel non-elected subject matter and place claim 50 in independent form by incorporating the limitations of claim 1 and therefore find support, for example, in the originally filed versions of these claims and the portions of the application cited as exemplary support for the amendment to claim 1. As the amendments to the claims are fully supported by the application as filed, no new matter is presented by the amendments.

The present paper further presents new claim 67. Claim 67 is fully supported by the application as filed and therefore presents no new matter. Specific support for new claim 67 may be found, for example, in the specification at page 35, lines 3-5, page 37, lines 21-22, page 40, lines 6-13, page 48, lines 1-5 and lines 8-11, and at page 127, lines 1-20 and Table 7. Accordingly, claim 67 is fully supported by the application as filed and presents no new matter.

Entry of the amendments to the claims is therefore respectfully requested under 37 C.F.R. § 1.111.

II. The Objection to the Specification

The specification stands objected to because of an alleged inconsistency between Genbank Accession No. NM_005577.1 and the nucleic acid sequence provided as SEQ ID NO.:4. In particular, the PTO contends that Genbank Accession No. NM_005577.1 describes a nucleotide sequence only 6489 nucleotides in length, substantially shorter than SEQ ID NO.:4.

In response, Applicants respectfully invite the PTO's attention to Exhibit 1, providing the nucleotide sequence identified as Genbank Accession No. NM_005577.1. Applicants note that Genbank has updated this accession number with a second sequence, Genbank Accession No. NM_005577.2 and believe that the PTO may have inadvertently viewed the replacement sequence rather than the original. In any event, Applicants believe that Genbank Accession No. NM_005577.1 and SEQ ID NO.:4 define the same sequence and that there is no discrepancy. Accordingly, Applicants respectfully request that the objection to the specification be withdrawn.

III. The Objections to the Claims

Claim 50 stands objected to for reciting SEQ ID NO.: 95 twice. Claim 50 has been amended to correct this error. Thus, Applicants believe this objection is moot and respectfully request its withdrawal.

Claims 52 and 53 stand objected to as depending from a rejected independent claim, but otherwise allowable. Applicants believe these objections are moot in view of the amendments to the claims and request their withdrawal.

III. The Rejection of Claim 50 Under 35 U.S.C. § 112, Second Paragraph

Claim 50 stands rejected under 35 U.S.C. § 112, second paragraph, as indefinite as the claimed compound allegedly cannot comprise a sequence selected from a closed group of sequences. Without acquiescing to the propriety of the rejection, claim 50, as amended, no longer recites compounds that comprise a sequence selected from a closed group of sequences. As such, Applicants believe the rejection is moot and respectfully request its withdrawal.

IV. The Rejection of Claims 1, 3, and 17 Under 35 U.S.C. § 102(e)

Claims 1, 3, and 17 stand rejected as allegedly anticipated under 35 U.S.C. § 102(e) by Cai *et al.* (International Patent Publication No. WO 2004/108916). In particular, the PTO contends that Cai *et al.* teaches an antisense oligonucleotide of which nucleotides 2-26 are 96% complementary to nucleotides 12,805-12,829 of SEQ ID NO.:4 as recited by, for example, claim 1. Thus, according to the PTO, Cai *et al.* anticipates claims 1, 3, and 17.

In response, Applicants respectfully submit that Cai *et al.* cannot anticipate claim 1, and thus claims 3 and 17 depending therefrom, as currently amended. First, the oligonucleotide of Cai *et al.* is 26 nucleotides long, yet the PTO's calculation of percent complementarity between the oligonucleotide of Cai *et al.* and the present SEQ ID NO.:4 ignores the mismatch at position 1 of the oligonucleotide of Cai *et al.* Each nucleotide of the oligonucleotide of Cai *et al.* should be considered when calculating the percentage of complementarity. When each nucleotide of the oligonucleotide of Cai *et al.* is so considered, this oligonucleotide is calculated to be 92.3% complementary to SEQ ID NO.: 4.

Claim 1 recites an antisense compound that is at least 94% complementary to nucleotides 12380-13493 of SEQ ID NO.:4. As the oligonucleotide of Cai *et al.* is less than 94% identical to this sequence, it does not teach this element of claim 1. As such, Cai *et al.* cannot anticipate claim 1 as amended, or claims 3 and 17 depending therefrom, since it fails to teach each and every element of the invention as presently claimed. *See Merck & Co. v. Teva Pharmaceuticals USA, Inc.*, 68 USPQ2d 185 (Fed. Cir. 2003). Accordingly, Applicants assert that the rejection of claims 1, 3, and 17 as anticipated by Cai *et al.* is moot in view of the amendments to the claims and therefore request its withdrawal.

V. The Rejection of Claims 1, 3, and 17 Under 35 U.S.C. § 103(a)

Claims 1, 3, 6, 8-11, 17, 54-60, and 62-66 stand rejected under 35 U.S.C. § 103(a) as allegedly obvious over Ruoy *et al.* (International Patent Publication No. WO 99/65241) in view of Morishita *et al.* (*Circulation*, 1998, 98:1898-1904) and Baracchini *et al.* (U.S. Patent No. 5,801,154). Claims 1, 3, 6, 8-11, 17, and 54-66 further stand rejected in view of this combination of references in further view of Ramasamy *et al.* (U.S. Patent No. 6,525,191).

In particular, the PTO contends that Ruoy *et al.* teaches antisense nucleic acids targeted to apolipoprotein(a) and use of such antisense nucleic acids to downregulate gene expression. The PTO acknowledges that Ruoy does not teach antisense compounds that are at least 90% complementary to the coding region of apolipoprotein(a). However, the PTO contends that Morishita *et al.* teaches phosphorothioate modified ribozymes and a DNA oligonucleotide targeted to the coding region of kringle 4 of apolipoprotein(a). The PTO relies on Baracchini *et al.* and Ramasamy *et al.* to teach various chemical modifications of oligonucleotides (*e.g.*, phosphorothioates, 2'-O-methoxyethyl sugar moieties, bicyclic nucleic acid sugar moieties, *etc.*). The PTO further contends that Baracchini states that the coding region of a gene is a preferred target for antisense modulation. Thus, according to the PTO, it would be obvious to one of ordinary skill in the art to make an antisense oligonucleotide to apolipoprotein(a) in view of the combination of Ruoy *et al.*, Morishita *et al.*, and Baracchini *et al.*

In response, Applicants respectfully submit that none of the references, either alone or in combination, provides a reason for one of ordinary skill in the art to select the particular region of the coding sequence of apolipoprotein(a) presently recited by independent claims 1 and 57. Further, Morishita *et al.*, as discussed below, specifically teaches away from antisense modulation of apolipoprotein(a), further demonstrating the non-obviousness of the claims.

A. The Legal Standard

The Supreme Court's decision in *Graham v. John Deere Co. of Kansas City*, 383 U.S.1 (1966) sets forth the controlling standard for assessing purported obviousness of a claimed invention: "[T]he scope and content of the prior art are ... determined; differences between the prior art and the claims at issue are ... ascertained; and the level of ordinary skill in the pertinent art resolved. Against this background the obviousness or nonobviousness of the subject matter is determined." *See id.* at 17–18.

The Supreme Court's recent decision in *KSR. Int'l Co. v. Teleflex*, 127 S.Ct. 1727, (2007) provides guidance regarding exactly how the differences between the prior art and claimed invention are analyzed to assess the obviousness or non-obviousness of the claims. As the Supreme Court explained, "interrelated teachings of multiple patents; the effects of demands known to the design community or present in the marketplace; and the background knowledge possessed by a person having ordinary skill in the art" can all be assessed "to determine whether there was an apparent reason to combine the known elements" as recited by the claim at issue. *See id.* at 1731 (2007). The Supreme Court expressly cautioned that this reason should be explicitly stated. *See id.* Thus, the PTO must identify an explicit reason to combine the elements of the prior art in the manner defined by the claims at issue.

Moreover, the prior art must be considered in its entirety, including portions of the prior art that teach away from the claimed subject matter. *See W.L. Gore & Associates, Inc. v. Garlock Inc.*, 220 USPQ 303 (Fed. Cir. 1984). A reference may be said to teach away when a person of ordinary skill, upon reading the reference,... would be led in a direction divergent from that taken by the applicant." *See Tec Air, Inc. v. Denso Mfg. Mich. Inc.*, 52 USPQ2d 1294, 1298, (Fed. Cir. 1999), quoted by *In re Haruna*, 58 USPQ2d 1517 (Fed. Cir. 2001).

Prior art references that teach away from the claimed combination should not be combined. *See In re Grasselli*, 218 USPQ 769 (Fed. Cir. 1983). Thus, if a prior art reference "did in fact teach away from [another prior art reference], then that finding alone can defeat

[an] obviousness” attack based on the combination of the two references. *See Winner International Royalty Corp. v. Wang*, 53 USPQ2d 1580 (Fed. Cir. 2000).

Further, “known disadvantages... that would naturally discourage search for new inventions may be taken into account in determining obviousness.” *See United States v. Adams*, 383 U.S. 39, 52; 148 USPQ 479, 484 (1966). In fact, the inventor’s achievement of the claimed invention by doing what others suggested should not be done is a fact strongly probative of nonobviousness. *See Kloser Speedsteel AB v. Crucible Inc.*, 230 USPQ 81 (Fed. Cir. 1986), *on rehearing* 231 USPQ 160 (Fed. Cir. 1986).

B. The Cited References Do Not Suggest an Antisense Compound at Least 90% or 94% Complementary to Nucleotides 12380-13493 of SEQ ID NO: 4

None of the cited references, either alone or in combination, teach or suggest an antisense compound at least 90% or 94% complementary to nucleotides 12380-13493 of SEQ ID NO: 4. Ruoy *et al.* neither teaches nor suggests that an antisense compound should be targeted to any particular region of the coding region of apolipoprotein(a). Further, as discussed extensively below, Morishita *et al.* teaches that antisense compounds, whether targeted to the coding region or otherwise, should not be used to modulate apolipoprotein(a) expression. As such, the combination of Ruoy *et al.* and Morishita *et al.* certainly fails to provide a reason why one of ordinary skill in the art should select the particular 1113 nucleotide region out of more than 13,000 nucleotides of SEQ ID NO.: 4 as a target for antisense modulation.

Moreover, neither Baracchini *et al.* nor Ramasamy *et al.* disclose anything regarding antisense modulation of apolipoprotein(a) expression. Rather, these references merely teach various chemical modifications of oligonucleotides and, in the case of Baracchini *et al.*, provides general teaching that antisense compounds can be targeted to the coding region of a gene. As such, neither of these references cure the deficiencies of Ruoy *et al.* and Morishita *et al.* discussed above. Accordingly, the combination of references, when considered as a whole, fails to teach or suggest each and every element of the invention as presently claimed. Further, the PTO has failed to identify a reason as required by the Supreme Court in *KSR v. Teleflex* “that would have prompted a person of ordinary skill in the relevant field to combine the elements in the way the claimed new invention does.” *See KSR* at 1731. Therefore, Applicants respectfully submit that the PTO has failed to establish *prima facie* obviousness of the claimed invention.

C. Morishita *et al.* Teaches Away from the Claimed Invention

In addition, Morishita *et al.* specifically teaches away from antisense modulation of apolipoprotein(a) expression. At the paragraph bridging pages 1898 and 1899 of Morishita *et*

al., the authors consider whether to use antisense compounds or ribozymes to modulate apolipoprotein(a) expression. Morishita *et al.* concludes that ribozymes are superior to antisense compounds for modulating expression of this gene because, according to Morishita *et al.*, ribozymes are more effective for inhibiting target gene expression and because of the difficulty of using antisense compounds to selectively inhibit apolipoprotein(a) expression.

Indeed, Morishita *et al.* uses a DNA oligonucleotide without ribozyme activity as a negative control (*see* Morishita *et al.* at page 1899, under the heading “Synthesis of Ribozyme ON and Selection of Sequence Targets.” This DNA oligonucleotide did not in fact inhibit apolipoprotein(a) expression. *See* Morishita *et al.* at page 1901, Figure 2. Therefore, Morishita *et al.* teaches that ribozymes, rather than antisense compounds as recited by the present claims, should be used to modulate apolipoprotein(a) expression and thus teaches away from the invention as presently claimed.

Since Morishita *et al.* teaches away from antisense compounds targeted to apolipoprotein(a), it is improper to include Morishita *et al.* in an obviousness rejection of claims drawn to such antisense compounds. *See In re Grasselli* and *Winner International*. Further, the conclusion of Morishita *et al.* that antisense compounds targeted to apolipoprotein(a) should not be used to modulate apolipoprotein(a) expression is strongly probative of the nonobviousness of Applicants’ invention. *See Kloser Speedsteel*. Accordingly, Applicants respectfully submit that Morishita *et al.* actually provides evidence that the claimed antisense compounds are not obvious, contrary to the PTO’s assertion otherwise.

D. The Obviousness Rejections Should Be Withdrawn

Applicants respectfully submit that the references cited by the PTO, whether considered alone or in combination, fail to teach or suggest each and every element of the invention recited by the independent claims, claims 1 and 57, of the present application. As such, Applicants respectfully submit that claims 1 and 57, and each of the claims depending therefrom, are not obvious over the references cited by the PTO. Therefore, Applicants respectfully request that the rejection of claims 1, 3, 6, 8-11, 17, 54-60, and 62-66 under 35 U.S.C. § 103(a) as obvious over Ruoy *et al.* in view of Morishita *et al.* and Baracchini *et al.* and of claims 1, 3, 6, 8-11, 17, and 54-66 over this combination of references in further view of Ramasamy *et al.* be withdrawn.

VI. Double Patenting

Claims 1, 3, 6, 8-11, and 54-57 stand provisionally rejected under the doctrine of obviousness-type double patenting over claims 1, 2, and 4-11 of copending application no. 10/485,113. Without acquiescing to the propriety of the rejection, Applicants believe the

rejection is moot in view of the abandonment of copending application no. 10/485,113.


Accordingly, Applicants respectfully request that the provisional rejection of claims 1, 3, 6, 8-11, and 54-57 for obviousness-type double patenting be withdrawn.

VII. Conclusion

In light of the above amendments and remarks, Applicants respectfully request that the PTO reconsider this application with a view towards allowance. The Examiner is invited to call the undersigned attorney at (650) 739-3949, if a telephone call could help resolve any remaining items.

Date: August 14, 2007

Respectfully submitted,



56,056

David C. Pauling

(Reg. No.)

For: Anthony M. Insogna

(Reg. No. 35,203)

JONES DAY



222 East 41st Street

New York, New York 10017

(212) 326-3939

EXHIBIT 1

Genbank Accesion No. NM_005577.1

[PubMed](#)
[Nucleotide](#)
[Protein](#)
[Genome](#)
[Structure](#)
[PMC](#)
[Taxonomy](#)
[OMIM](#)
[Books](#)

Search for

[Limits](#)
[Preview/Index](#)
[History](#)
[Clipboard](#)
[Details](#)

Display Show Hide: ☐ sequence ☐ all but gene, CDS and mRNA

Range: from to ☐ Reverse complemented strand Features: ☒ STS

☐ 1: NM_005577. Reports ...[gi:5031884] The record has been replaced by [116292749](#)

[Comment](#) [Features](#) [Sequence](#)

LOCUS NM_005577 13938 bp mRNA linear PRI 19-SEP-2006
 DEFINITION Homo sapiens lipoprotein, Lp(a) (LPA), mRNA.
 ACCESSION NM_005577 XM_926329 XM_941794
 VERSION NM_005577.1 GI:5031884
 KEYWORDS .
 SOURCE Homo sapiens (human)
 ORGANISM [Homo sapiens](#)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
 Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 13938)
 AUTHORS Becker, L., Nesheim, M.E. and Koschinsky, M.L.
 TITLE Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation
 JOURNAL Biochemistry 45 (32), 9919-9928 (2006)
 PUBMED [16893192](#)
 REMARK GeneRIF: Cultured human hepatoma cells secrete an oxidase activity that dramatically enhances the rate of covalent Lp(a) assembly.

REFERENCE 2 (bases 1 to 13938)
 AUTHORS Sotiriou, S.N., Orlova, V.V., Al-Fakhri, N., Ihanus, E., Economopoulou, M., Isermann, B., Bdeir, K., Nawroth, P.P., Preissner, K.T., Gahmberg, C.G., Koschinsky, M.L. and Chavakis, T.
 TITLE Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin
 JOURNAL FASEB J. 20 (3), 559-561 (2006)
 PUBMED [16403735](#)
 REMARK GeneRIF: data demonstrate that Lp(a), via its apo(a) moiety, is a ligand for the beta2-integrin Mac-1, thereby facilitating inflammatory cell recruitment to atherosclerotic plaques; these observations suggest a novel mechanism for atherogenic properties of Lp(a)

REFERENCE 3 (bases 1 to 13938)
 AUTHORS Unluhizarci, K., Muhtaroglu, S., Kabak, S., Bayram, F. and Kelestimur, F.
 TITLE Serum lipoprotein (a) levels in patients with diabetic foot lesions
 JOURNAL Diabetes Res. Clin. Pract. 71 (2), 119-123 (2006)
 PUBMED [16122830](#)
 REMARK GeneRIF: Lp (a) levels may have a pathogenetic role in the development of gangrenous foot lesions in patients with diabetes mellitus.

REFERENCE 4 (bases 1 to 13938)
 AUTHORS Edelstein, C., Yousef, M. and Scanu, A.M.
 TITLE Elements in the C terminus of apolipoprotein [a] responsible for

the binding to the tenth type III module of human fibronectin

JOURNAL J. Lipid Res. 46 (12), 2673-2680 (2005)

PUBMED [16150826](#)

REMARK GeneRIF: binding sites responsible for binding to fibronectin

REFERENCE 5 (bases 1 to 13938)

AUTHORS Devlin,C.M., Lee,S.J., Kuriakose,G., Spencer,C., Becker,L., Grosskopf,I., Ko,C., Huang,L.S., Koschinsky,M.L., Cooper,A.D. and Tabas,I.

TITLE An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo

JOURNAL Arterioscler. Thromb. Vasc. Biol. 25 (8), 1704-1710 (2005)

PUBMED [15905467](#)

REMARK GeneRIF: high levels of apo(a)/Lp(a), perhaps acting via a specific cell-surface binding domain, inhibit hepatic clearance of remnants, leading to high plasma levels of remnant lipoproteins and markedly enhanced atherosclerosis

REFERENCE 6 (bases 1 to 13938)

AUTHORS Nardulli,M., Durlach,V., Pepe,G. and Angles-Cano,E.

TITLE Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma

JOURNAL Thromb. Haemost. 94 (1), 75-81 (2005)

PUBMED [16113787](#)

REMARK GeneRIF: lipoprotein(a) has a role in homocysteine-enhanced antifibrinolysis in human plasma

REFERENCE 7 (bases 1 to 13938)

AUTHORS Song,K.H., Ko,S.H., Kim,H.W., Ahn,Y.B., Lee,J.M., Son,H.S., Yoon,K.H., Cha,B.Y., Lee,K.W. and Son,H.Y.

TITLE Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria

JOURNAL Diabetes Care 28 (7), 1718-1723 (2005)

PUBMED [15983325](#)

REMARK GeneRIF: Lp(a) is an independent risk factor for the progression of diabetic nephropathy in type 2 diabetic patients with overt proteinuria.

REFERENCE 8 (bases 1 to 13938)

AUTHORS Schneider,M., Witztum,J.L., Young,S.G., Ludwig,E.H., Miller,E.R., Tsimikas,S., Curtiss,L.K., Marcovina,S.M., Taylor,J.M., Lawn,R.M., Innerarity,T.L. and Pitas,R.E.

TITLE High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins

JOURNAL J. Lipid Res. 46 (4), 769-778 (2005)

PUBMED [15654123](#)

REMARK GeneRIF: mechanism by which increased circulating levels of Lp[a] could contribute to atherogenesis

REFERENCE 9 (bases 1 to 13938)

AUTHORS Eliassen,K.A., Brodal,B.P., Svindland,A., Osmundsen,H., Ronning,H., Djurovic,S. and Berg,K.

TITLE Activity of peroxisomal enzymes, and levels of polyamines in LPA-transgenic mice on two different diets

JOURNAL (er) Lipids Health Dis 4, 23 (2005)

PUBMED [16202171](#)

REMARK GeneRIF: Suggest connection between peroxisomal enzyme activity & presence of human LPA gene in murine genome. Effect may be result of changes in oxidative processes in lipid metabolism rather than from direct effect of LPA gene on peroxisomal gene expression.

REFERENCE 10 (bases 1 to 13938)

AUTHORS Parson,W., Kraft,H.G., Niederstatter,H., Lingenhel,A.W., Kochl,S.,

Fresser, F. and Utermann, G.

TITLE A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a)

JOURNAL Hum. Mutat. 24 (6), 474-480 (2004)

PUBMED [15523644](#)

REFERENCE 11 (bases 1 to 13938)

AUTHORS Lamanuzzi, L.B., Mtairag el, M., Pepe, G. and Angles-Cano, E.

TITLE Neutrophils stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a)

JOURNAL Thromb. Haemost. 92 (5), 1066-1075 (2004)

PUBMED [15543335](#)

REMARK GeneRIF: Stimulation of PMNs by apo(a) results in the formation of elastase-derived apo(a) fragments that produce a concentration-dependent decrease in the formation of plasmin

REFERENCE 12 (bases 1 to 13938)

AUTHORS Diaz-Peromingo, J.A., Carbajal, D.G. and Alban-Salgado, A.

TITLE Lipoprotein (a) in patients on hemodialysis

JOURNAL Acta Med. Austriaca 31 (3), 73-75 (2004)

PUBMED [15515480](#)

REMARK GeneRIF: Changes in Lp(a) levels were found and perhaps these changes may be related to the episodic inflammation affecting patients on hemodialysis.

REFERENCE 13 (bases 1 to 13938)

AUTHORS Anderson, N.L., Polanski, M., Pieper, R., Gatlin, T., Tirumalai, R.S., Conrads, T.P., Veenstra, T.D., Adkins, J.N., Pounds, J.G., Fagan, R. and Lobley, A.

TITLE The human plasma proteome: a nonredundant list developed by combination of four separate sources

JOURNAL Mol. Cell Proteomics 3 (4), 311-326 (2004)

PUBMED [14718574](#)

REFERENCE 14 (bases 1 to 13938)

AUTHORS Frohlich, J., Dobiasova, M., Adler, L. and Francis, M.

TITLE Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease

JOURNAL Physiol Res 53 (5), 481-486 (2004)

PUBMED [15479125](#)

REMARK GeneRIF: Our findings suggest that Lp(a) is more strongly associated with aCAD+ in women than in men.

REFERENCE 15 (bases 1 to 13938)

AUTHORS Bogavac-Stanojevic, N., Djurovic, S., Jelic-Ivanovic, Z., Spasojevic-Kalimanovska, V. and Kalimanovska-Ostic, D.

TITLE Circulating transforming growth factor-beta1, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease

JOURNAL Clin. Chem. Lab. Med. 41 (7), 893-898 (2003)

PUBMED [12940514](#)

REMARK GeneRIF: Blood levels are higher in coronary artery disease patients compared with normal values.

REFERENCE 16 (bases 1 to 13938)

AUTHORS Gazzaruso, C., Garzaniti, A., Falcone, C., Puija, A., Geroldi, D., Giordanetti, S. and Fratino, P.

TITLE Lipoprotein(a), apolipoprotein(a) polymorphism and restenosis after intracoronary stent placement in Type 2 diabetic patients

JOURNAL J. Diabetes Complicat. 17 (3), 135-140 (2003)

PUBMED [12738397](#)

REMARK GeneRIF: Lp(a) and apo(a) polymorphisms do not appear to be reliable markers of restenosis in patients with Type 2 diabetes mellitus.

REFERENCE 17 (bases 1 to 13938)

AUTHORS Nassir, F., Xie, Y. and Davidson, N.O.
TITLE Apolipoprotein[a] secretion from hepatoma cells is regulated in a size-dependent manner by alterations in disulfide bond formation
JOURNAL J. Lipid Res. 44 (4), 816-827 (2003)
PUBMED [12562843](#)
REFERENCE 18 (bases 1 to 13938)
AUTHORS Tian, H., Han, L., Ren, Y., Li, X. and Liang, J.
TITLE Lipoprotein(a) level and lipids in type 2 diabetic patients and their normoglycemic first-degree relatives in type 2 diabetic pedigrees
JOURNAL Diabetes Res. Clin. Pract. 59 (1), 63-69 (2003)
PUBMED [12482643](#)
REMARK GeneRIF: Positive correlation of Lp(a) between type 2 diabetic patients and their offspring, suggesting a potential genetic control for Lp(a) levels in type 2 diabetics families.
REFERENCE 19 (bases 1 to 13938)
AUTHORS Barre, D.E.
TITLE Apolipoprotein (a) mediates the lipoprotein (a)-induced biphasic shift in human platelet cyclic AMP
JOURNAL Thromb. Res. 112 (5-6), 321-324 (2003)
PUBMED [15041277](#)
REMARK GeneRIF: apo(a) mediates the Lp(a)-induced biphasic response in platelet c-AMP as the result of platelet exposure to increasing levels of Lp(a), up to a concentration of 25 mg/dl Lp(a)
REFERENCE 20 (bases 1 to 13938)
AUTHORS Kapetanopoulos, A., Fresser, F., Millonig, G., Shaul, Y., Baier, G. and Utermann, G.
TITLE Direct interaction of the extracellular matrix protein DANCE with apolipoprotein(a) mediated by the kringle IV-type 2 domain
JOURNAL Mol. Genet. Genomics 267 (4), 440-446 (2002)
PUBMED [12111551](#)
REFERENCE 21 (bases 1 to 13938)
AUTHORS Nawawi, H.M., Muhajir, M., Kian, Y.C., Mohamud, W.N., Yusoff, K. and Khalid, B.A.
TITLE Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients
JOURNAL Diabetes Res. Clin. Pract. 56 (3), 221-227 (2002)
PUBMED [11947970](#)
REMARK GeneRIF: Type of diabetes and waist-hip ratio are important determinants of levels in diabetic patients [LIPOPROTEIN (A)]
REFERENCE 22 (bases 1 to 13938)
AUTHORS Cerrato, P., Imperiale, D., Fornengo, P., Bruno, G., Cassader, M., Maffei, P., Cavallo Perin, P., Pagano, G. and Bergamasco, B.
TITLE Higher lipoprotein (a) levels in atherothrombotic than lacunar ischemic cerebrovascular disease
JOURNAL Neurology 58 (4), 653-655 (2002)
PUBMED [11365151](#)
REMARK GeneRIF: Lipoprotein (a) promotes large vessel atheromatosis rather than small vessel arteriolosclerosis and favors thrombosis on atheromatous plaques by suppressing local fibrinolysis.
REFERENCE 23 (bases 1 to 13938)
AUTHORS Geethanjali, F.S., Jose, V.J. and Kanagasabapathy, A.S.
TITLE Lipoprotein (a) phenotypes in south Indian patients with coronary artery disease
JOURNAL Indian Heart J 54 (1), 50-53 (2002)
PUBMED [11999086](#)
REMARK GeneRIF: Plasma lipoprotein (a) levels are significantly elevated in patients with coronary artery disease as compared to controls. The contribution of lipoprotein (a) phenotype to the lipoprotein (a) levels in our population, if any, is modest.

REFERENCE 24 (bases 1 to 13938)
AUTHORS Cabrinety,N., Pisonero,M.J., Ajram,J., Armenteras,A. and Cuatrecasas,J.M.
TITLE Lipoprotein (a) in obese children with a family history of cardiovascular disease
JOURNAL J. Pediatr. Endocrinol. Metab. 15 (1), 77-80 (2002)
PUBMED [11822583](#)
REMARK GeneRIF: children's group with BMI > 30 and with family history of CVD presented higher levels in comparison to the less obese group with family history of CVD

REFERENCE 25 (bases 1 to 13938)
AUTHORS Xue,S., Madison,E.L. and Miles,L.A.
TITLE The Kringle V-protease domain is a fibrinogen binding region within Apo(a)
JOURNAL Thromb. Haemost. 86 (5), 1229-1237 (2001)
PUBMED [11816712](#)
REMARK GeneRIF: The Apo(a) Kringle V-protease domain binds to plasmin-treated fibrinogen, competing with and sharing binding sites with Lp(a), and possibly participating in the Lp(a)-fibrinogen interaction.

REFERENCE 26 (bases 1 to 13938)
AUTHORS Ogorelkova,M., Kraft,H.G., Ehnholm,C. and Utermann,G.
TITLE Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians
JOURNAL Hum. Mol. Genet. 10 (8), 815-824 (2001)
PUBMED [11285247](#)

REFERENCE 27 (bases 1 to 13938)
AUTHORS Klose,R., Fresser,F., Kochl,S., Parson,W., Kapetanopoulos,A., Fruchart-Najib,J., Baier,G. and Utermann,G.
TITLE Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta - and gamma -chains
JOURNAL J. Biol. Chem. 275 (49), 38206-38212 (2000)
PUBMED [10980194](#)

REFERENCE 28 (bases 1 to 13938)
AUTHORS Rosby,O. and Berg,K.
TITLE LPA gene: interaction between the apolipoprotein(a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level
JOURNAL J. Intern. Med. 247 (1), 139-152 (2000)
PUBMED [10672142](#)

REFERENCE 29 (bases 1 to 13938)
AUTHORS Ogorelkova,M., Gruber,A. and Utermann,G.
TITLE Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians
JOURNAL Hum. Mol. Genet. 8 (11), 2087-2096 (1999)
PUBMED [10484779](#)

REFERENCE 30 (bases 1 to 13938)
AUTHORS Edelstein,C., Shapiro,S.D., Klezovitch,O. and Scanu,A.M.
TITLE Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology
JOURNAL J. Biol. Chem. 274 (15), 10019-10023 (1999)
PUBMED [10187779](#)

REFERENCE 31 (bases 1 to 13938)
AUTHORS Niemeier,A., Willnow,T., Dieplinger,H., Jacobsen,C., Meyer,N., Hilpert,J. and Beisiegel,U.
TITLE Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro
JOURNAL Arterioscler. Thromb. Vasc. Biol. 19 (3), 552-561 (1999)

PUBMED [10073957](#)
REFERENCE 32 (bases 1 to 13938)
AUTHORS Bonen,D.K., Nassir,F., Hausman,A.M. and Davidson,N.O.
TITLE Inhibition of N-linked glycosylation results in retention of intracellular apo[a] in hepatoma cells, although nonglycosylated and immature forms of apolipoprotein[a] are competent to associate with apolipoprotein B-100 in vitro
JOURNAL J. Lipid Res. 39 (8), 1629-1640 (1998)
PUBMED [9717723](#)
REFERENCE 33 (bases 1 to 13938)
AUTHORS Kochl,S., Fresser,F., Lobentanz,E., Baier,G. and Utermann,G.
TITLE Novel interaction of apolipoprotein(a) with beta-2 glycoprotein I mediated by the kringle IV domain
JOURNAL Blood 90 (4), 1482-1489 (1997)
PUBMED [9269765](#)
REFERENCE 34 (bases 1 to 13938)
AUTHORS Edelstein,C., Italia,J.A. and Scanu,A.M.
TITLE Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments
JOURNAL J. Biol. Chem. 272 (17), 11079-11087 (1997)
PUBMED [9111002](#)
REFERENCE 35 (bases 1 to 13938)
AUTHORS Edelstein,C., Italia,J.A., Klezovitch,O. and Scanu,A.M.
TITLE Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a]
JOURNAL J. Lipid Res. 37 (8), 1786-1801 (1996)
PUBMED [8864963](#)
REFERENCE 36 (bases 1 to 13938)
AUTHORS Grainger,D.J., Kemp,P.R., Liu,A.C., Lawn,R.M. and Metcalfe,J.C.
TITLE Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice
JOURNAL Nature 370 (6489), 460-462 (1994)
PUBMED [8047165](#)
REFERENCE 37 (bases 1 to 13938)
AUTHORS Salonen,E.M., Jauhiainen,M., Zardi,L., Vaheri,A. and Ehnholm,C.
TITLE Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it
JOURNAL EMBO J. 8 (13), 4035-4040 (1989)
PUBMED [2531657](#)
REFERENCE 38 (bases 1 to 13938)
AUTHORS Frank,S.L., Klisak,I., Sparkes,R.S., Mohandas,T., Tomlinson,J.E., McLean,J.W., Lawn,R.M. and Lusk,A.J.
TITLE The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen
JOURNAL Hum. Genet. 79 (4), 352-356 (1988)
PUBMED [3410459](#)
REFERENCE 39 (bases 1 to 13938)
AUTHORS McLean,J.W., Tomlinson,J.E., Kuang,W.J., Eaton,D.L., Chen,E.Y., Fless,G.M., Scanu,A.M. and Lawn,R.M.
TITLE cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
JOURNAL Nature 330 (6144), 132-137 (1987)
PUBMED [3670400](#)
COMMENT PROVISIONAL [REFSEQ](#): This record has not yet been subject to final NCBI review. The reference sequence was derived from [X06290.1](#).
[WARNING] On Oct 20, 2006 this sequence was replaced by [gi:116292749](#).
On or before Mar 4, 2006 this sequence version replaced

```
FEATURES             Location/Qualifiers
     source            1..13938
                        /organism="Homo sapiens"
                        /mol_type="mRNA"
                        /db_xref="taxon:9606"
                        /chromosome="6"
                        /map="6q26"
     gene              1..13938
                        /gene="LPA"
                        /note="synonyms: LP, AK38, APOA"
                        /db_xref="GeneID:4018"
                        /db_xref="HGNC:6667"
                        /db_xref="HPRD:01063"
                        /db_xref="MIM:152200"
     CDS                46..13692
                        /gene="LPA"
                        /EC_number="3.4.21.-"
                        /GO_component="extracellular region [pmid 14718574]"
                        /GO_function="endopeptidase inhibitor activity [pmid
                        3047165]; lipid transporter activity; peptidase activity;
                        serine-type endopeptidase activity"
                        /GO_process="circulation [pmid 3047165]; lipid metabolism
                        [pmid 3047165]; lipid transport; proteolysis"
                        /note="Apolipoprotein Lp(a); antiangiogenic AK38 protein;
                        apolipoprotein(a)"
                        /codon_start=1
                        /product="lipoprotein, Lp(a)"
                        /protein_id="NP_005568.1"
                        /db_xref="GI:5031885"
                        /db_xref="GeneID:4018"
                        /db_xref="HGNC:6667"
                        /db_xref="HPRD:01063"
                        /db_xref="MIM:152200"
                        /translation="MEHKENVLLLLLLFLKSAAPEQSHVVQDCYHGDGQSYRGTYSTTV
                        TGRTCQAWSSMTPHQHNRRTTENYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNL
                        TQCSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTG
                        RTCQAWSSMTPHSHSRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQT
                        CSDAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRT
                        CQAWSSMTPHSHSRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCS
                        DAEGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCQ
                        AWSSMTPHSHSRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDA
                        EGTAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAW
                        SSMTPHSHSRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEG
                        TAVAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSS
                        MTPHSHSRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTA
                        VAPPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSSMT
                        PHSHSRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTAVA
                        PPTVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSSMTPH
                        SHSRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTAVAPP
                        TVTPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSSMTPHSH
                        SRTP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTAVAPPTV
                        TPVPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSSMTPHSHSR
                        TP EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTAVAPPTVP
                        VPSLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSSMTPHSHSRTP
                        EYYPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTAVAPPTVTPVP
                        SLEAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSSMTPHSHSRTP EY
                        YPNAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTAVAPPTVTPVPSL
                        EAPSEQAPTEQRPGVQECYHGNGQSYRGTYSTTVTGRTCAWSSMTPHSHSRTP EYYP
                        NAGLIMNYCRNPDAVAAPCYTRDPGVRWEYCNLQCSDAEGTAVAPPTVTPVPSLE
```

[illegible]

sig peptide

46..102

/gene="LPA"

```
/note="signal peptide (AA -19 to -)"
```

mat peptide

103..13689

```
/gene="LPA"
```

```
/product="apolipoprotein (a) (AA 1- 4529)"
```

STS

12579..12709


```

/ gene="LPA"
/ standard_name="GDB:595276"
/ db_xref="UniSTS:158018"
STS 13694..13824
/ gene="LPA"
/ standard_name="STS-X06290"
/ db_xref="UniSTS:72928"
STS 13696..13938
/ gene="LPA"
/ standard_name="D6S1951"
/ db_xref="UniSTS:43503"
polyA_site 13938
/ gene="LPA"
/ note="polyA site"

```

ORIGIN

```

1 ctgggattgg gacacacttt ctggacactg ctggccagtc ccaaaatgga acataaggaa
61 gtggttcttc tacttctttt atttctgaaa tcagcagcac ctgagcaaag ccatgtggtc
121 caggattgct accatgggtga tggacagagt tctcagggca cgtactccac cactgtcaca
181 ggaaggacct gccaaagcttg gtcatctatg acaccacatc aacataatag gaccacagaa
241 aactacccaa atgctggcct gatcatgaac tactgcagga atccagatgc tgtggcagct
301 ccttattggt atacgaggga tcccgggtgc aggtgggagt actgcaacct gacgcaatgc
361 tcagacgcag aagggactgc cgtcgcgcct ccgactgtta ccccggttcc aagcctagag
421 gctccttccg aacaagcacc gactgagcaa aggcctgggg tgcaggagtg ctaccatggt
481 aatggacaga gttatcgagg cacatactcc accactgtca caggaagaac ctgccaagct
541 tggatcatcta tgacaccaca ctgcatagt cggaccccag aatactacc aaatgctggc
601 ttgatcatga actactgcag gaatccagat gctgtggcag ctcttattg ttatacgagg
661 gatcccggtg tcaggtggga gtactgcaac ctgacgcaat gctcagacgc agaagggact
721 gccgtcgcgc ctccgactgt taccgggtt ccaagcctag aggctccttc cgaacaagca
781 ccgactgagc aaaggcctgg ggtgcaggag tgctaccatg gtaatggaca gagttatcga
841 ggcacatact ccaccactgt cacaggaaga acctgccaag ctgggtcatc tatgacacca
901 cactcgcata gtcggacccc agaatactac ccaaagtctg gcttgatcat gaactactgc
961 aggaatccag atgctgtggc agctccttat tggtatacga gggatcccgg tgtcaggtgg
1021 gagtactgca acctgacgca atgctcagac gcagaaggga ctgccgtcgc gcctccgact
1081 gttaccccgg ttccaagcct agaggctcct tccgaacaag caccgactga gcaaaggcct
1141 ggggtgcagg agtgctacca ttgtaatgga cagagttatc gaggcacata ctccaccact
1201 gtcacaggaa gaacctgcca agcttggtca tctatgacac cactcgcga tagtcggacc
1261 ccagaatact acccaaatgc tggcttgatc atgaactact gcaggaatcc agatgctgtg
1321 gcagctcctt attgttatac gagggatccc ggtgtcaggt gggagtactg caacctgacg
1381 caatgctcag acgcagaagg gactgccgtc gcgctccga ctgttaccgc ggttccaagc
1441 ctagaggctc cttccgaaca agcaccgact gagcaaaggc ctggggtgca ggagtgtac
1501 catggtaatg gacagagtta tcgaggcaca tactccacca ctgtcacagg aagaacctgc
1561 caagcttggc catctatgac accacactcg catagtcgga cccagaata ctacccaaat
1621 gctggcttga tcatgaacta ctgcaggaat ccagatgctg tggcagctcc ttattgttat
1681 acgaggggat ccggtgtcag gtgggtatc tcgaacctga cgcaatgctc agacgtgaa
1741 gggactgccg tcgcgcctcc gactgttacc ccggttccaa gcctagaggc tccttccgaa
1801 caagcaccga ctgagcaaaag gcctggggtg caggagtgtc accatggtaa tggacagagt
1861 tatcgaggca catactccac cactgtcaca ggaagaacct gccaaagcttg gtcactatg
1921 acaccacact cgcatagtcg gaccccagaa tactacccaa atgctggctt gatcatgaac
1981 tactgcagga atccagatgc tgtggcagct ccttattggt atacgaggga tcccgggtgc
2041 aggtgggagt actgcaacct gacgcaatgc tcagacgcag aagggactgc cgtcgcgcct
2101 ccgactgtta ccccggttcc aagcctagag gctccttccg aacaagcacc gactgagcaa
2161 aggcctgggg tgcaggagtg ctaccatggt aatggacaga gttatcgagg cacatactcc
2221 accactgtca caggaagaac ctgccaagct tggatcatcta tgacaccaca ctgcatagt
2281 cggaccccag aatactacc aaatgctggc ttgatcatga actactgcag gaatccagat
2341 gctgtggcag ctcttattg ttatacgagg gatcccggtg tcaggtggga gtactgcaac
2401 ctgacgcaat gctcagacgc agaagggact gccgtcgcgc ctccgactgt taccgggtt
2461 ccaagcctag aggctccttc cgaacaagca ccgactgagc aaaggcctgg ggtgcaggag
2521 tgctaccatg gtaatggaca gagttatcga ggcacatact ccaccactgt cacaggaaga
2581 acctgccaaag cttggtcatc tatgacacca cactcgcata gtcggacccc agaatactac
2641 ccaaagtctg gcttgatcat gaactactgc aggaatccag atgctgtggc agctccttat

```

```
2701 tgttatacga gggatccccg tgtcagggtg gagtactgca acctgacgca atgctcagac
2761 gcagaaggga ctgccgtcgc gcctccgact gttacccccg ttccaagcct agaggctcct
2821 tccgaacaag caccgactga gcaaaggcct ggggtgcagg agtgctacca tggtaatgga
2881 cacagttatc gaggcacata ctccaccact gtcacaggaa gaacctgcca agcttgggca
2941 tctatgacac cacactcgca tagtcggacc ccagaatact acccaaatgc tggcttgatc
3001 atgaactact gcaggaatcc agatgctgtg gcagctcctt attgttatac gagggatccc
3061 ggtgtcagggt gggagtactg caacctgacg caatgctcag acgcagaagg gactgccgtc
3121 gcgcctccga ctgttaccctt ggttccaagc cttagaggctc cttccgaaca agcaccgact
3181 gagcaaaggc ctgggggtgca ggagtgtctac catggtaatg gacagagtta tcgaggcaca
3241 tactccacca ctgtcacagg aagaacctgc caagcttggg catctatgac accacactcg
3301 catagtcgga ccccagaata ctacccaaat gctggcttga tcatgaacta ctgcaggaat
3361 ccagatgctg tggcagctcc ttattgttat acgagggatc ccggtgtcag gtgggagtac
3421 tgcaacctga cgcaatgctc agacgcagaa gggactgccg tcgcgcctcc gactgttacc
3481 ccggttccaa gcctagaggc tccttccgaa caagcaccga ctgagcaaag gcctgggggtg
3541 caggagtgtc accatggtaa tggacagagt tatcgaggca catactccac cactgtcaca
3601 ggaagaacct gccaaagctg gtcattctatg acaccacact cgcatagtcg gaccccagaa
3661 tactacccaa atgctggctt gatcatgaac tactgcagga atccagatgc tgtggcagct
3721 ccttattgtt atacgaggga tcccgggtgc aggtgggagt actgcaacct gacgcaatgc
3781 tcagacgcag aagggactgc cgtcgcgcct ccgactgtta ccccggttcc aagcctagag
3841 gtccttccg aacaagcacc gactgagcaa aggcctgggg tgcaggagtgc ctaccatggt
3901 aatggacaga gttatcgagg cacatactcc accactgtca caggaagaac ctgccaagct
3961 tggatcatcta tgacaccaca ctgcgcatagt cggaccccag aatactacct aaatgctggc
4021 ttgatcatga actactgcag gaatccagat gctgtggcag ctcttatttg ttatacgagg
4081 gatcccggtg tcaggtggga gtactgcaac ctgacgcaat gctcagacgc agaagggact
4141 gccgtcgcgc ctccgactgt taccgcgggt ccaagcctag aggtccttc cgaacaagca
4201 ccgactgagc aaaggcctgg ggtgcaggag tgctaccatg gtaatggaca gagtatcga
4261 ggcacatact ccaccactgt cacaggaaga acctgccaag cttggtcatc tatgacacca
4321 cactcgcata gtcggacccc agaatactac ccaaagtctg gcttgatcat gaactactgc
4381 aggaatccag atgctgtggc agctccttat tgttatacga gggatccccg tgtcagggtg
4441 gagtactgca acctgacgca atgctcagac gcagaaggga ctgccgtcgc gcctccgact
4501 gttacccccg ttccaagcct agaggctcct tccgaacaag caccgactga gcaaaggcct
4561 ggggtgcagg agtgctacca tggtaatgga cacagttatc gaggcacata ctccaccact
4621 gtcacaggaa gaacctgcca agcttgggta tctatgacac cacactcgca tagtcggacc
4681 ccagaatact acccaaatgc tggcttgatc atgaactact gcaggaatcc agatgctgtg
4741 gcagctcctt attgttatac gagggatccc ggtgtcagggt gggagtactg caacctgacg
4801 caatgctcag acgcagaagg gactgccgtc gcgcctccga ctgttaccct gggtccaagc
4861 ctagagggtc cttccgaaca agcaccgact gagcaaaggc ctgggggtgca ggagtgtctac
4921 catggtaatg gacagagtta tcgaggcaca tactccacca ctgtcacagg aagaacctgc
4981 caagcttggg catctatgac accacactcg catagtcgga ccccagaata ctacccaaat
5041 gctggcttga tcatgaacta ctgcaggaat ccagatgctg tggcagctcc ttattgttat
5101 acgagggatc ccggtgtcag gtgggagtac tgcaacctga cgcaatgctc agacgcagaa
5161 gggactgccg tcgcgcctcc gactgttacc ccggttccaa gcctagaggc tccttccgaa
5221 taagcaccga ctgagcaaag gcctgggggtg caggagtgtc accatggtaa tggacagagt
5281 tctcgaggca cactgtcaca ggaagaacct gccaaagctg gtcattctatg
5341 acaccacact cgcatagtcg gacccagaaa tactacccaa atgctggctt gatcatgaac
5401 tactgcagga atccagatgc tgtggcagct ccttattgtt atacgaggga tcccgggtgc
5461 aggtgggagt actgcaacct gacgcaatgc tcagacgcag aagggactgc cgtcgcgcct
5521 ccgactgtta ccccggttcc aagcctagag gctccttccg aacaagcacc gactgagcaa
5581 aggcctgggg tgcaggagtgc ctaccatggt aatggacaga gttatcgagg cacatactcc
5641 accactgtca caggaagaac ctgccaagct tggatcatcta tgacaccaca ctgcgcatagt
5701 cggaccccag aatactacct aaatgctggc ttgatcatga actactgcag gaatccagat
5761 gctgtggcag ctcttatttg ttatacgagg gatcccgggtg tcaggtggga gtactgcaac
5821 ctgacgcaat gctcagacgc agaagggact gccgtcgcgc ctccgactgt taccgcgggtt
5881 ccaagcctag aggtcctctc cgaacaagca ccgactgagc aaaggcctgg ggtgcaggag
5941 tgctaccatg gtaatggaca gagttatcga ggcacatact ccaccactgt cacaggaaga
6001 acctgccaag cttgggtcatc tatgacacca cactcgcata gtcggacccc agaatactac
6061 ccaaagtctg gcttgatcat gaactactgc aggaatccag atgctgtggc agctccttat
6121 tgttatacga gggatccccg tgtcagggtg gagtactgca acctgacgca atgctcagac
6181 gcagaaggga ctgccgtcgc gcctccgact gttacccccg ttccaagcct agaggctcct
6241 tccgaacaag caccgactga gcaaaggcct ggggtgcagg agtgctacca tggtaatgga
```

6301	cagagttatc	gaggcacata	ctccaccact	gtcacaggaa	gaacctgcca	agcttgggtca
6361	tctatgacac	cacactcgca	tagtcggacc	ccagaatact	acccaaatgc	tggcttgatc
6421	atgaactact	gcaggaatcc	agatgctgtg	gcagtcctt	attgttatac	gagggatccc
6481	gggtgctcaggt	gggagtactg	caacctgacg	caatgctcag	acgcagaagg	gactgccgtc
6541	gcgcctccga	ctgttacc	ggttccaagc	ctagaggctc	cttccgaaca	agcaccgact
6601	gagcaaaagc	ctggggtgca	ggagtgtctac	catggtaatg	gacagagtta	tgcaggcaca
6661	tactccacca	ctgtcacagg	aagaacctgc	caagcttggg	catctatgac	accacactcg
6721	catagtcgga	ccccagaata	ctacccaaat	gctggcttga	tcatgaacta	ctgcaggaat
6781	ccagatgctg	tggcagctcc	ttattgttat	acgagggatc	ccgggtgtcag	gtgggagtac
6841	tgcaacctga	cgcaatgctc	agacgcagaa	gggactgccg	tcgcgcctcc	gactgttacc
6901	ccggttccaa	gcctagaggc	tccttccgaa	caagcaccga	ctgagcaaag	gcctggggtg
6961	caggagtgtc	accatggtaa	tggacagagt	tatcgaggca	catactccac	cactgtcaca
7021	ggaagaacct	gccaagcttg	gtcatctatg	acaccacact	cgcatagtcg	gaccccagaa
7081	tactacccaa	atgctggctt	gatcatgaac	tactgcagga	atccagatgc	tgtggcagct
7141	ccttattgtt	atacaggga	tcccgggtgtc	aggtgggagt	actgcaacct	gacgcaatgc
7201	tcagacgcag	aagggactgc	cgtcgcgcct	ccgactgtta	ccccggttcc	aagcctagag
7261	gctccttccg	aacaagcacc	gactgagcaa	aggcctgggg	tgcaggagt	ctaccatggg
7321	aatggacaga	gttatcgagg	cacatactcc	accactgtca	caggaagaac	ctgccaagct
7381	tggatcatcta	tgacaccaca	ctcgcatagt	cggaccccag	aatactaccc	aatgctggc
7441	ttgatcatga	actactgcag	gaatccagat	gctgtggcag	ctccttattg	ttatacgagg
7501	gatcccgggtg	tcagggtgga	gtactgcaac	ctgacgcaat	gctcagacgc	agaagggact
7561	gccgtcgcgc	ctccgactgt	taccccggtt	ccaagcctag	aggctccttc	cgaacaagca
7621	ccgactgagc	aaaggcctgg	ggtgcaggag	tgctaccatg	gtaatggaca	gagttatcga
7681	ggcacatact	ccaccactgt	cacaggaaga	acctgccaa	cttgggtcatc	tatgacacca
7741	cactcgcata	gtcggacccc	agaatactac	ccaaatgctg	gcttgatcat	gaactactgc
7801	aggaatccag	atgctgtggc	agctccttat	tgttatacga	gggatcccgg	tgtcagggtg
7861	gagtactgca	acctgacgca	atgctcagac	gcagaaggga	ctgccgtcgc	gcctccgact
7921	gttaccocgg	ttccaagcct	agaggctcct	tccgaacaag	caccgactga	gcagaggcct
7981	ggggtgcagg	agtgtctacca	cggtaatgga	cagagttatc	gaggcacata	ctccaccact
8041	gtcactggaa	gaacctgcca	agcttgggtca	tctatgacac	cacactcgca	tagtcggacc
8101	ccagaatact	acccaaatgc	tggcttgatc	atgaactact	gcaggaatcc	agatgctgtg
8161	gcagtcctt	attgttatac	gagggatccc	gggtgcaggt	gggagtactg	caacctgacg
8221	caatgctcag	acgcagaagg	gactgccgtc	gcgcctccga	ctgttacc	ggttccaagc
8281	ctagaggctc	cttccgaaca	agcaccgact	gagcaaaggc	ctggggtgca	ggagtgtctac
8341	catggtaatg	gacagagtta	tcgaggcaca	tactccacca	ctgtcacagg	aagaacctgc
8401	caagcttggg	catctatgac	accacactcg	catagtcgga	ccccagaata	ctacccaaat
8461	gctggcttga	tcatgaacta	ctgcaggaat	ccagatgctg	tggcagctcc	ttattgttat
8521	acgagggatc	ccgggtgtcag	gtgggagtac	tgcaacctga	cgcaatgctc	agacgcagaa
8581	gggactgccg	tcgcgcctcc	gactgttacc	ccggttccaa	gcctagaggc	tccttccgaa
8641	caagcaccga	ctgagcaaag	gcctggggtg	caggagtgtc	accatggtaa	tggacagagt
8701	tatcgaggca	catactccac	cactgtcaca	ggaagaacct	gccaagcttg	gtcatctatg
8761	acaccacact	cgcatagtcg	gaccccagaa	tactacccaa	atgtctggctt	gatcatgaac
8821	tactgcagga	atccagatgc	tgtggcagct	ccttattgtt	atacaggga	tcccgggtgtc
8881	aggtgggagt	actgcaacct	gacgcaatgc	tcagacgcag	aagggactgc	cgtcgcgcct
8941	ccgactgtta	ccccggttcc	aagcctagag	gctccttccg	aacaagcacc	gactgagcag
9001	aggcctgggg	tgcaggagt	ctaccacggg	aatggacaga	gttatcgagg	cacatactcc
9061	accactgtca	ctggaagaac	ctgccaagct	tggtcatcta	tgacaccaca	ctcgcatagt
9121	cggaccccag	aatactaccc	aatgctggc	ttgatcatga	actactgcag	gaatccagat
9181	gctgtggcag	ctccttattg	ttatacgagg	gatcccgggtg	tcagggtgga	gtactgcaac
9241	ctgacgcaat	gctcagacgc	agaagggact	gccgtcgcgc	ctccgactgt	taccccggtt
9301	ccaagcctag	aggctccttc	cgaacaagca	ccgactgagc	agaggcctgg	ggtgcaggag
9361	tgctaccacg	gtaatggaca	gagttatcga	ggcacatact	ccaccactgt	cactggaaga
9421	acctgccaa	cttgggtcatc	tatgacacca	cactcgcata	gtcggacccc	agaatactac
9481	ccaaatgctg	gcttgatcat	gaactactgc	aggaatccag	atgctgtggc	agctccttat
9541	tgttatacga	gggatcccgg	tgtcagggtg	gagtactgca	acctgacgca	atgctcagac
9601	gcagaaggga	ctgccgtcgc	gcctccgact	gttaccocgg	ttccaagcct	agaggctcct
9661	tccgaacaag	caccgactga	gcagaggcct	ggggtgcagg	agtgtctacca	cggtaatgga
9721	cagagttatc	gaggcacata	ctccaccact	gtcactggaa	gaacctgcca	agcttgggtca
9781	tctatgacac	cacactcgca	tagtcggacc	ccagaatact	acccaaatgc	tggcttgatc
9841	atgaactact	gcaggaatcc	agatgctgtg	gcagctcctt	attgttatac	gagggatccc

```
9901 ggtgtcaggt gggagtactg caacctgacg caatgctcag acgcagaagg gactgccgtc
9961 ggcgcctccga ctgttaccctt ggttccaagc cttagaggctc cttccgaaca agcaccgact
10021 gagcagaggc ctgggggtgca ggagtgtctac cacggtaatg gacagagtta tcgaggcaca
10081 tactccacca ctgtcactgg aagaacctgc caagcttgggt catctatgac accacactcg
10141 catagtccga ccccgagaata ctacccaaat gctggcttga tcatgaacta ctgcaggaat
10201 ccagatcctg tggcagcccc ttattgttat acgagggatc ccagtgtcag gtgggagtac
10261 tgcaacctga cacaatgctc agacgcagaa gggactgccg tcgcgcctcc aactattacc
10321 ccgattccaa gcctagaggc tccttctgaa caagcaccaa ctgagcaaag gcctgggggtg
10381 caggagtgtc accacggaaa tggacagagt tatcaaggca catacttcat tactgtcaca
10441 ggaagaacct gccaaagcttg gtcattctat acaccacact cgcatagtcg gacccagca
10501 tactacccaa atgtgtgctt gatcaagaac tactgccgaa atccagatcc tgtggcagcc
10561 ccttggtgtt atacaacaga tcccagtgtc aggtggggagt actgcaacct gacacgatgc
10621 tcagatgcag aatggactgc cttcgtccct ccgaatgtta ttctggctcc aagcctagag
10681 gctttttttg aacaagcact gactgaggaa acccccgggg tacaggactg ctactaccat
10741 tatggacaga gttaccgagg cacatactcc accactgtca caggaagaac ttgccaagct
10801 tgggtcatcta tgacaccaca ccagcatagt cggaccccag aaaactacct aaatgctggc
10861 ctgaccagga actactgcag gaatccagat gctgagattc gcccttgggtg ttacaccatg
10921 gatcccagtg tcaggtggga gtactgcaac ctgacacaat gcctggtgac agaatcaagt
10981 gtccttgcaa ctctcacggt ggtcccagat ccaagcacag aggcttcttc tgaagaagca
11041 ccaacggagc aaagccccgg ggtccaggat tgctaccatg gtgatggaca gagttatcga
11101 ggctcattct ctaccactgt cacaggaagg acatgtcagt cttggtcctc tatgacacca
11161 cactggcatc agaggacaac agaattattat ccaaattggtg gcctgaccag gaactactgc
11221 aggaatccag atgttgagat tagtccttgg tgttatacca tggatcccaa tgtcagatgg
11281 gctactgca acctgacaca atgtccagtg acagaatcaa gtgtccttgc gacgtccacg
11341 gctgtttctg aacaagcacc aacggagcaa agccccacag tccaggactg ctaccatggt
11401 gatggacaga gttatcgagg ctcatctctc accactgtta caggaaggac atgtcagctc
11461 tgggtcctcta tgacaccaca ctggcatcag agaaccacag aatactacct aaatggtggc
11521 ctgaccagga actactgcag gaatccagat gctgagattc gcccttgggtg ttataccatg
11581 gatcccagtg tcagatggga gtactgcaac ctgacgcaat gtccagtgat ggaatcaact
11641 ctctcaciaa ctcccacggt ggtcccagtt ccaagcacag agcttccttc tgaagaagca
11701 ccaactgaaa acagcactgg ggtccaggac tgctaccgag gtgatggaca gagttatcga
11761 ggcacactct ccaccactat cacaggaaga acatgtcagt cttggtcgtc tatgacacca
11821 cattggcatc ggaggatccc attatactat ccaaattgctg gcctgaccag gaactactgc
11881 aggaatccag atgttgagat tcgccccttg tgttacacca tggatcccag tgtcaggtgg
11941 gagtactgca acctgacacg atgtccagtg acagaatcga gtgtcctcac aactcccaca
12001 gtggccccgg ttccaagcac agaggctcct tctgaacaag caccacctga gaaaagccct
12061 gtggtccagg attgtacca tgggtgatgga cggagttatc gaggcataat ctccaccact
12121 gtcacaggaa ggacctgtca atcttgggtc tctatgatac cacactggca tcagaggacc
12181 ccagaaaact acccaaatgc tggcctgacc gagaactact gcaggaatcc agattctggg
12241 aaacaacctt ggtgttacac aaccgatccg tgtgtgaggt gggagtactg caatctgaca
12301 caatgtcag aaacagaatc aggtgtccta gagactccca ctgttgttcc agttccaagc
12361 attgaggctc attctgaagc agcaccaact gagcaaaccc ctgtggtccg gcagtgctac
12421 catggtaatg gccagagtta tcgaggcaca ttctccacca ctgtcacagc aaggacatgt
12481 caatcttgggt catccatgac accacaccgg catcagagga ccccgaaaaa ctacccaaat
12541 gatggcctga caatgaacta ctgcaggaat ccagatgccg atacaggccc ttggtgtttt
12601 accatggacc ccagcatcag gtgggagtac tgcaacctga cgcgatgtc agacacagaa
12661 gggactgtgg tcgtcctctc gactgtcatc caggttccaa gcctagggcc tcttctgaa
12721 caagactgta tgtttgggaa tgggaaagga taccggggca agaaggcaac cactgttact
12781 gggacgccat gccaggaatg ggctgccag gagccccata gacacagcac gttcattcca
12841 gggacaaata aatgggcagg tctggaaaaa aattactgcc gtaacctga tggtgacatc
12901 aatggctcct ggtgtacac aatgaatcca agaaaacttt ttgactactg tgatatccct
12961 ctctgtgcat cctcttcatt tgattgtggg aagcctcaag tggagccgaa gaaatgtcct
13021 ggaagcattg taggggggtg tgtggcccac ccacattcct ggccctggca agtcagtctc
13081 agaacaaggt ttggaaagca cttctgtgga ggcaccttaa tatccccaga gtgggtgctg
13141 actgtgtctc actgtttgaa gaagtctca aggccttcat cctacaaggt catcctgggt
13201 gcacaccaag aagtgaacct cgaatctcat gttcaggaaa tagaagtgtc taggctgttc
13261 ttggagccca cacaagcaga tattgccttg ctaaagctaa gcaggcctgc cgtcatcact
13321 gacaaagtaa tgccagcttg tctgccatcc ccagactaca tggtcaccgc caggactgaa
13381 tgttacatca ctggctgggg agaaacccaa ggtacctttg ggactggcct tctcaaggaa
13441 gccagctcc ttgttattga gaatgaagtg tgcaatcact ataagtatat ttgtgctgag
```

13501 catttggcca gaggcactga cagttgccag ggtgacagtg gagggcctct ggtttgcttc
13561 gagaaggaca aatacathtt acaaggagtc acttcttggg gtcttggctg tgcacgcccc
13621 aataagcctg gtgtctatgc tcgtgtttca aggtttgtta cttggattga gggaatgatg
13681 agaaataatt aattggacgg gagacagagt gaagcatcaa cctacttaga agctgaaacg
13741 tgggtaagga tttagcatgc tggaaataat agacagcaat caaacgaaga cactgttccc
13801 agctaccagc tatgccaaac cttggcattt ttggtatttt tgtgtataag cttttaaggt
13861 ctgactgaca aattctgtat taagggtgtca tagctatgac atttgtaaa aataaactct
13921 gcacttattt tgatttga

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 19 2007 13:56:00